DaVita Inc. (NYSE: DVA) is a Healthcare company (Medical - Care Facilities) with a market capitalization of $10.9B. The Maz Rating grades it against the other companies in its sector.
DaVita Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $173.00, DaVita Inc. trades at 13.3x trailing earnings and 0.8x sales, with an EV/EBITDA of 8.5. Over the last twelve months it generated about $14.2B of revenue and $819M of net income. It runs a gross margin of 31.0%, an operating margin of 14.8% and a net margin of 6.5%. It shows return on equity of -133.2%, return on invested capital of 10.7% and a free cash flow yield of 11.9%. On the balance sheet: a debt-to-equity ratio of -22.66 and a current ratio of 1.41. Over the past 52 weeks the share price ranged from $101.00 to $247.49, with a beta of 0.86.
DaVita Inc. does not currently pay a dividend.
23 Wall Street analyst ratings cover the stock: 10 Buy, 12 Hold and 1 Sell, for a Hold consensus. This is the sell side's view, separate from the Maz Rating.
DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, DaVita Inc. (DVA) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 92.0% / 30% · (Cash+Inv) / Mkt Cap (36m) 8.62% / 30% · Interest income / Revenue 0.00% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 92.0% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 4.84% / 33% · Receivables / Mkt Cap (36m) 26.3% / 49% · Interest income / Revenue 0.00% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 92.0% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 4.84% / 33.33% · Receivables / Mkt Cap (24m) 26.3% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 63.3% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 3.95% / 33.33% · Receivables / Avg Assets (4Q) 17.1% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| FTSE | Debt / Total Assets 60.4% / 33.33% · (Cash+ST Inv) / Total Assets 3.18% / 33.33% · (Cash+Recv) / Total Assets 20.4% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
No. As of September 2026, DaVita Inc. (DVA) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. DaVita Inc. is over the AAOIFI limit on Debt / Mkt Cap (36m).
DaVita Inc. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.